ATLANTA, Jan. 5, 2016 /PRNewswire/ -- Global Genomics Group ("G3") announced that it has entered into a research collaboration with Sanofi (EURONEXT: SAN; NYSE: SNY) to identify new signaling pathways and targets involved in the etiology of coronary artery disease.
Under the terms of the agreement, Sanofi and G3 will utilize G3's proprietary platform with data from its G3LOBAL DatabaseTM to further unravel the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with such novel signaling pathways.
"Our G3LOBAL DatabaseTM has been developed as a tool that enables drug developers and biomedical research scientists to better understand molecular networks that underlie human disease and thus improve the drug discovery and development process," said Szilard Voros, M.D., founder and chief executive officer of G3. "We believe that precision phenotyping, pan-omics and systems-biology driven bioinformatics are the key components of target identification, validation and the elucidation of novel pathways."
G3 will receive undisclosed payments from Sanofi for the collaboration.
About the G3LOBAL DatabaseTM
G3's G3LOBAL DatabaseTM is derived from the GLOBAL clinical study (NCT01738828), an international prospective, multi-center study recruiting up to 10,000 patients to characterize novel disease networks and biomarkers. GLOBAL is the largest and most comprehensive pan-omic study combining whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics, lipidomics, and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows the precise classification of disease in patients.
About Global Genomics Group (G3)
G3 is a global leader in pan-omics and investigates biological networks that lead to the development of disease to identify novel biomarkers and therapeutic targets. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and systems-biology driven bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.
For additional information, please visit www.globalgenomicsgroup.com
VP, Finance and Operations
SOURCE Global Genomics Group (G3)